NOAH Compendium

Printed from NOAH Compendium ( (c) Copyright NOAH Compendium 2024. All Rights Reserved.
Date: Thursday, February 29, 2024 16:16

Description: MSD-AH
Release 21.214
Bravecto® Spot-on Solution for Dogs
Species: Dogs
Therapeutic indication: Pharmaceuticals: Ectoparasiticides: For dogs, For cats
Active ingredient: Fluralaner
Product:Bravecto® Spot-on Solution for Dogs
Bravecto® Spot-on Solution for Dogs
Product index: Bravecto® Spot-on Solution for Dogs
Withdrawal notes: Not applicable.
Qualitative and quantitative composition
Each ml contains 280 mg fluralaner.
Each pipette delivers:
Pipette content (ml)
Fluralaner (mg)
for very small dogs 2 -4.5 kg
for small dogs >4.5 - 10 kg
for medium-sized dogs >10 - 20 kg
for large dogs > 20 - 40 kg
for very large dogs >40 - 56 kg
For the full list of excipients, see 'Pharmaceutical particulars' section.
Pharmaceutical form
Spot on solution.
Clear colourless to yellow solution.
Clinical particulars
Target Species
Indications for use
For the treatment of tick and flea infestations in dogs.
This veterinary medicinal product is a systemic insecticide and acaricide that provides:
- immediate and persistent flea (Ctenocephalides felis and Ctenocephalides canis) killing activity for 12 weeks, and
- immediate and persistent tick (Ixodes ricinus, Rhipicephalus sanguineus and Dermacentor reticulatus) killing activity for 12 weeks.
For the treatment of demodicosis caused by Demodex canis.
For the treatment of sarcoptic mange (Sarcoptes scabiei var. canis) infestation.
Fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.
The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Special warnings for each target species
Parasites need to start feeding on the host to become exposed to fluralaner; therefore the risk of the transmission of parasite borne diseases cannot be excluded.
Special Precautions for use
Care should be taken to avoid contact with the eyes of the animal.
Do not use directly on skin lesions.
Do not wash or allow the dog to become immersed in water or swim in water courses within 3 days after treatment.
In the absence of available data, this veterinary medicinal product should not be used on puppies less than 8 weeks old and /or dogs weighing less than 2 kg.
The product should not be administered at intervals shorter than 8 weeks as the safety at shorter intervals has not been tested.
This product is for topical use and should not be administered orally.
Operator warnings
Contact with the product should be avoided and disposable protective gloves obtained with this product at the point of sale must be worn when handling the product for the following reasons:
Hypersensitivity reactions have been reported in a small number of people, which can potentially be serious.
Persons with a hypersensitivity to fluralaner or to any of the excipients should avoid any exposure to the product.
The product binds to skin and may also bind to surfaces after spillage of the product. Skin rashes, tingling or numbness have been reported in a small number of individuals after skin contact.
If skin contact does occur, wash the affected area immediately with soap and water. In some cases, soap and water are not sufficient to remove the product spilled on the fingers.
Contact with the product may also occur when handling the treated animal.
Make sure that your animal’s application site is no longer noticeable before resuming contact with the site of application. This includes cuddling the animal and sharing a bed with the animal. It takes up to 48 hours for the application site to become dry but it will be noticeable for longer.
If skin reactions occur, consult a physician and show them the product packaging.
People with a sensitive skin or known allergy in general e.g. to other veterinary medicinal products of this type should handle the veterinary medicinal product as well as treated animals with caution.
This product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water.
This product is harmful after ingestion. Keep the product in the original packaging until use, in order to prevent children from getting direct access to the product. A used pipette should immediately be disposed of. In case of accidental ingestion, seek medical advice and show the package leaflet or the label to the physician.
The product is highly flammable. Keep away from heat, sparks, open flame or other sources of ignition.In case of spillage onto, for example table or floor surfaces, remove excess product using paper tissue and clean the area with detergent.
Adverse Reactions
Mild and transient skin reactions such as erythema or alopecia at the application site were commonly observed in clinical trials (1.2% of treated dogs).
Emesis, lethargy and anorexia have been reported very rarely in spontaneous reports after the use of this product.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Use during pregnancy or lactation
The safety of the veterinary medicinal product in breeding, pregnant and lactating dogs has been demonstrated. Can be used in breeding, pregnant and lactating dogs.
None known.
Fluralaner is highly bound to plasma proteins and might compete with other highly bound active substances such as non-steroidal anti-inflammatory drugs (NSAIDs) and the coumarin derivative warfarin. Incubation of fluralaner in the presence of carprofen or warfarin in dog plasma at maximum expected plasma concentrations did not reduce the protein binding of fluralaner, carprofen or warfarin.
During laboratory and clinical field testing, no interactions between Bravecto spot-on solution for dogs and routinely used veterinary medicinal products were observed.
Amounts to be administered and administration route
For spot-on use.
Bravecto should be administered in accordance with the following table (corresponding to a dose of 25 - 56 mg fluralaner/kg body weight):
Description: Bravecto Dog Dosage Guide
For dogs above 56 kg body weight, use a combination of two pipettes that most closely matches the body weight.
Method of administration to dogs:
Step 1: Immediately before use, open the sachet and remove the pipette. Put on gloves. The pipette should be held by the base or by the upper rigid portion below the cap in an upright position (tip up) for opening it. The cap should be rotated clockwise or counter clockwise one full turn. The cap will stay on the pipette; it is not possible to remove it. The pipette is open and ready for application when the breaking of the seal is felt.
Description: Bravecto spot on
Step 2: The dog should be standing or lying with its back horizontal during application. Place the pipette tip vertically against the skin between the shoulder blades of the dog.
Step 3: Squeeze the pipette gently and apply the entire contents directly to the dog's skin in one (when volume is small) or several spots along the dog's dorsalline from the shoulder to the base of the tail. Avoid the application of more than 1 ml of solution at any oen spot as it could cause some of the solution to run or drip off the dog.
Description: Bravecto Spot On Dog image
Treatment schedule:
For optimal control of tick and flea infestation, the product should be administered at intervals of 12 weeks.
For the treatment of Demodex canis mite infestations, a single dose of the product should be applied. As demodicosis is a multi-factorial disease, it is advisable to also treat any underlying disease appropriately.
For the treatment of sarcoptic mange infestations (Sarcoptes scabiei var. canis), a single dose of the product should be applied. The need for and frequency of re-treatment should be in accordance with the advice of the prescribing veterinarian.
No adverse reactions were observed following topical administration to puppies aged 8 – 9 weeks and weighing 2.0 – 3.7 kg treated with overdoses of up to 5 times the maximum recommended dose (56 mg, 168 mg and 280 mg fluralaner/kg body weight) on three occasions at shorter intervals than recommended (8-week intervals).
There were no findings on reproductive performance and no findings of concern on offspring viability when fluralaner was administered orally to Beagle dogs at overdoses of up to 3 times the maximum recommended dose (up to 168 mg/kg body weight of fluralaner).
Fluralaner was well tolerated in Collies with a deficient multidrug-resistance-protein 1 (MDR1 -/-) following single oral administration at 3 times the maximum recommended dose (168 mg/kg body weight). No treatment-related clinical signs were observed.
Withdrawal periods
Not applicable.
Pharmacological particulars
Pharmacotherapeutic group: Ectoparasiticides for systemic use.
ATCvet code: QP53B E02
Pharmacodynamic properties
Fluralaner is an acaricide and insecticide. It is efficacious against ticks (Ixodes spp., Dermacentor spp. and Rhipicephalus sanguineus), fleas (Ctenocephalides spp.), Demodex canis mites and sarcoptic mange (Sarcoptes scabiei var. canis) on the dog.
The onset of efficacy is within 8 hours for fleas (C. felis) and 12 hours for ticks (I. ricinus).
Fluralaner has a high potency against ticks and fleas by exposure via feeding, i.e. it is systemically active on target parasites.
Fluralaner is a potent inhibitor of parts of the arthropod nervous system by acting antagonistically on ligand-gated chloride channels (GABA-receptor and glutamate-receptor).
In molecular on-target studies on insect GABA receptors of flea and fly, fluralaner is not affected by dieldrin resistance.
In in vitro bio-assays, fluralaner is not affected by proven field resistances against amidines (tick), organophosphates (tick, mite), cyclodienes (tick, flea, fly), macrocyclic lactones (sea lice), phenylpyrazoles (tick, flea), benzophenyl ureas (tick), pyrethroids (tick, mite) and carbamates (mite).
The product contributes towards the control of the environmental flea populations in areas to which treated dogs have access.
Newly emerged fleas on a dog are killed before viable eggs are produced. An in vitro study also demonstrated that very low concentrations of fluralaner stop the production of viable eggs by fleas. The flea life cycle is broken due to the rapid onset of action and long lasting efficacy against adult fleas on the animal and the absence of viable egg production.
Pharmacokinetic particulars
Fluralaner is readily absorbed from the topical administration site into the hair, skin and subjacent tissues, from where it is slowly absorbed into the vascular system. A plateau is seen in plasma between 7 and 63 days post administration, after which concentrations decline slowly. The prolonged persistence and slow elimination from plasma (t1/2 = 21 days) and the lack of extensive metabolism provide effective concentrations of fluralaner for the duration of the inter-dosing interval. Unchanged fluralaner is excreted in faeces and to a very low extent in urine.
Pharmaceutical particulars
Diethyltoluamide (DEET)
Major incompatibilities
None known.
Shelf life of the veterinary medicinal product as packaged for sale:
Bravecto 112.5 mg spot-on solution: 2 years
Bravecto 250 mg / 500 mg / 1,000 mg / 1,400 mg spot-on solution: 3 years
Special precautions for storage
This veterinary medicinal product does not require any special temperature storage conditions. The pipettes should be kept in the outer packaging to prevent solvent loss or moisture uptake. The sachets should only be opened immediately prior to use.
Immediate packaging
Unit dose pipette made of laminated aluminium/polypropylene foil closed with an HDPE cap and packed in a laminated aluminium foil sachet.
Each carton box contains 1 or 2 pipettes and a pair of gloves per pipette.
Not all pack sizes may be marketed.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Marketing Authorisation Holder (if different from distributor)
UK(NI): Intervet International B.V., The Netherlands
Marketing Authorisation Number
UK(GB): Vm 01708/0515, 18, 20, 23, 26
UK(NI): EU/2/13/158/016-017, 020-021, 024-025, 028-029, 030-031
Significant changes
Date of the first authorisation or date of renewal
Date of first authorisation: 11/02/2014
Date of first renewal: 05/02/2019
Date of revision of the text
UK(GB): 30/07/2021
UK(NI): 11/06/2021
Any other information
For animal treatment only. Keep out of the sight and reach of children.
Legal category
Legal category: POM-V
GTIN description:Bravecto Spot On Cat 500 mg
GTIN description:Bravecto Spot On Cat 112.5 mg
GTIN description:Bravecto Spot On Cat 250 mg